Compare BioNTech SE - ADR (BNTX) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Constellation Energy Corporation — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while Constellation Energy Corporation trades at $257.06 (market cap $91.57B). The key difference: Constellation Energy Corporation is far larger — about 4× BioNTech SE - ADR's market cap, and Constellation Energy Corporation pays a 0.67% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CEG | |
|---|---|---|
Market Cap | $22.86B | $91.57B |
Sector | Health | Energy |
52-Week High | $119.34 | $403.95 |
52-Week Low | $83.89 | $236.50 |
Enterprise Value | $6.53B | $113.24B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
